Position in NVAX
as of Jun 30, 2026
· filed Jul 15, 2026
Position Value
$265,408
+$36,064 QoQ
Shares Held
28,175
0.0% QoQ
Ownership
0.017%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#124
of 263 holders
Holding Since
Dec 2021
3 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVAX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026INDEPENDENT FINANCIAL GROUP, LLC holds $5,426,584 across 14 Biotechnology names. NVAX ranks #9 (4.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
14,410 | $1,174,559 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,089 | $679,035 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,345 | $668,101 | |
| 4 | HALO |
Halozyme Therapeutics, Inc.
|
5,857 | $458,427 | |
| 5 | CTNM |
Contineum Therapeutics, Inc.
|
27,021 | $442,874 | |
| 6 | EXEL |
Exelixis, Inc.
|
6,871 | $373,851 | |
| 7 | SLS |
SELLAS Life Sciences Group, Inc.
|
23,250 | $343,170 | |
| 8 | CRSP |
CRISPR Therapeutics AG
|
6,062 | $330,621 |
All Filings in NVAX
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $265,408 | 28,175 | Shares | Sole | 2026-07-15 | |
| 2026-03-31 | $229,344 | 28,175 | Shares | Sole | 2026-05-15 | |
| 2021-12-31 | $210,312 | 1,470 | Shares | Sole | 2026-06-15 | |
| No filing history on record for this holder in this stock. | ||||||